| Gene symbol | STAT3 | Synonyms | ADMIO, ADMIO1, APRF, HIES | Type of gene | protein-coding |
| Chromosome | 17 | Map location | 17q21.2 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | signal transducer and activator of transcription 3 | ||||
| GTO ID | GTC1850 |
| Trial ID | NCT03394144 |
| Disease | Advanced Solid Tumor |
| Altered gene | STAT3 |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | ISIS-STAT3rx|AZD9150|ISIS 481464|IONIS-STAT3-2.5Rx |
| Phase | Phase1 |
| Recruitment status | Completed |
| Title | A Phase I, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD9150 Monotherapy and AZD9150 in Combination With Durvalumab in Japanese Patients With Advanced Solid Malignancies |
| Year | 2018 |
| Country | Japan |
| Company sponsor | AstraZeneca |
| Other ID(s) | D5660C00017 |
| Vector information | |||
|
|||
| Cohort1: Danvatirsen | |||||||||||
|
|||||||||||
| Cohort2: Danvatirsen_Durvalumab | |||||||||||
|
|||||||||||